

Azamacrocyclic Metal Complexes as CXCR4 Antagonists

Tomohiro Tanaka,^[a] Tetsuo Narumi,^{*[a]} Taro Ozaki,^[a] Akira Sohma,^[a] Nami Ohashi,^[a] Chie Hashimoto,^[a] Kyoko Itotani,^[a] Wataru Nomura,^[a] Tsutomu Murakami,^[b] Naoki Yamamoto,^[b, c] and Hirokazu Tamamura^{*[a]}

The chemokine receptor CXCR4 is a member of the seven transmembrane GPCR family, which is implicated in multiple diseases, including HIV infection, cancers, and rheumatoid arthritis. Low-molecular-weight nonpeptidic compounds, including AMD3100 and various pyridyl macrocyclic zinc(II) complexes, have been identified as selective antagonists of CXCR4. In the present study, structure–activity relationship studies were performed by combining the common structural features of alkylamino and pyridyl macrocyclic antagonists. Several

new zinc(II) or copper(II) complexes demonstrated potent anti-HIV activity, strong CXCR4-binding activity, and significant inhibitory activity against Ca^{2+} mobilization induced by CXCL12 stimulation. These results may prove useful in the design of novel CXCR4 antagonists, and the compounds described could potentially be developed as therapeutics against CXCR4-relevant diseases or chemical probes to study the biological activity of CXCR4.


Introduction

The chemokine receptor CXCR4, which transduces signals of its endogenous ligand, CXCL12/stromal cell-derived factor-1 (SDF-1),^[1–4] is classified as a member of the seven transmembrane GPCR family, and plays a physiological role via its interaction with CXCL12 in chemotaxis,^[5] angiogenesis,^[6,7] and neurogenesis^[8,9] in embryonic stages. CXCR4 is, however, relevant to multiple diseases including HIV infection/AIDS,^[10,11] metastasis of several types of cancer,^[12–14] leukemia cell progression,^[15,16] and rheumatoid arthritis (RA),^[17,18] and is considered an attractive drug target to combat these diseases. Thus, inhibitors targeting CXCR4 are expected to be useful for drug discovery.

Several CXCR4 antagonists have been reported,^[19–35] including our discovery of the highly potent CXCR4 antagonist T140, a 14-mer peptide with a disulfide bridge, its smaller derivative, the 5-mer cyclic peptide FC131, and several other potent analogues.^[19,24–26,28–30] Clinical development of these peptidic antagonists could be pursued using specific administration strategies involving biodegradable microcapsules.^[14,36] However, herein we focus on novel nonpeptidic low-molecular-weight CXCR4 antagonists. To date, AMD3100 (1),^[20,22] Dpa-Zn complex (2),^[37] KRH-1636,^[27] and other compounds^[31–35] have been developed in this and other laboratories as low-molecular-weight nonpeptidic CXCR4 antagonists. The present study reports structure–activity relationship studies based on the combination of common structural motifs, such as xylene scaffolds and cationic moieties that are present in the aforementioned compounds.

Results and Discussion

In order to determine spatially suitable positioning of cationic moieties, *p*- and *m*-xylenes were utilized as spacers. Cationic moieties such as bis(pyridin-2-ylmethyl)amine (dipicolylamine), 1,4,7,10-tetraazacyclododecane (cyclen), and 1,4,8,11-tetraaza-



cyclotetradecane (cyclam) were introduced as R^1 and R^2 (Figure 1). This combination of R^1 , R^2 , and spacer groups led to the design and synthesis of compounds 12–31.

The CXCR4 binding activity of synthetic compounds was assessed based on the inhibition of [^{125}I]CXCL12 binding to Jurkat cells, which express CXCR4.^[38] The percent inhibition of all compounds at $1\ \mu\text{M}$ is shown in Table 1. Seven compounds (16, 17, 20–22, 28, and 29, Table 1) resulted in greater than 87% inhibition. The high activity of 16 is consistent with re-

[a] T. Tanaka, Dr. T. Narumi, T. Ozaki, A. Sohma, N. Ohashi, C. Hashimoto, K. Itotani, Dr. W. Nomura, Prof. H. Tamamura
Institute of Biomaterials and Bioengineering
Tokyo Medical and Dental University
2-3-10 Kandasurugadai, Chiyoda-ku, Tokyo 101-0062 (Japan)
Fax: (+81) 3-5280-8039
E-mail: tamamura.mr@tmd.ac.jp

[b] Dr. T. Murakami, Prof. N. Yamamoto
AIDS Research Center, National Institute of Infectious Diseases
1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640 (Japan)

[c] Prof. N. Yamamoto
Department of Microbiology, Yong Loo Lin School of Medicine
National University of Singapore, Singapore 117597 (Singapore)

Supporting information for this article is available on the WWW under <http://dx.doi.org/10.1002/cmdc.201000548>.




Figure 1. The structures of aromatic spacers (upper) and cationic moieties (R^1 and R^2). The shaded circle represents the position of the metal cation (Zn^{II} or Cu^{II}) in the chelate.

sults reported previously.^[20,22] The anti-HIV activities of **17** and **29**, which contain only cyclam or cyclal rings, were reported by De Clercq et al.^[39,40] Compounds with only pyridine and/or cyclen rings did not show any high binding activity. The presence of azamacrocyclic rings is presumably indispensable to the interaction of these compounds with CXCR4, and the size of rings appears to be important because not only compounds **16** and **17**, with two cyclam rings in the molecule, but also compounds **28** and **29**, with two cyclal rings, have remarkably more potent CXCR4 binding activity than compounds **14** and **15**, which have two cyclen rings. Compound **22**, with a *p*-xylene moiety, exhibited higher activity than compound **23**, which has an *m*-xylene moiety, indicating that *p*-xylene is more suitable than *m*-xylene as a spacer for approximate positioning of cationic moieties. At 0.1 μM , compound **22** resulted in 86% inhibition of [^{125}I]CXCL12 binding, while the other six compounds exhibited 37–66% inhibition. The IC_{50} value of compound **22** was estimated to be 37 nM.

ZnCl_2 was added to phosphate-buffered saline (PBS) solutions of these 20 compounds, **12–31**, to form zinc(II) complexes. The percent inhibition for each compound at 1 μM against [^{125}I]CXCL12 binding was determined and is given in Table 1. Zinc complexation of **12–15**, **18**, **19**, and **23** resulted in a remarkable increase in CXCR4 binding activity compared to the corresponding zinc-free compounds. These molecules contain dipicolylamine and/or cyclen moieties, suggesting that chelation of the nitrogen atoms with the zinc(II) ion significantly affects their interactions with CXCR4. The high activity of the zinc chelates of **12** and **13** is consistent with results provided in our previous paper.^[37] Additionally, the anti-HIV activity of zinc complexes of **14** and **15** was reported by Kimura et al.^[41] For compounds with only dipicolylamine and/or cyclen macrocycles as cationic moieties (**12–15**, **18**, and **19**), zinc complexation is critical to achieve high binding activity; the correspond-

ing zinc-free compounds exhibit no significant activity. Compounds **16**, **17**, **20–22**, **28**, and **29** demonstrated high binding affinity in metal-free states as well as in zinc complexation states, indicating that zinc complexation of either of the macrocyclic rings in these compounds is not essential for high activity. The CXCR4 binding activity and anti-HIV activity of the zinc complex of **16** were reported previously.^[42,43] Measured inhibition percentages for 0.1 μM of the zinc complexes of **12**, **14–23**, **28**, and **29** are given in Table 1. The zinc complexes of **20–22**, **28**, and **29** at 0.1 μM exhibited greater than 79% inhibition of [^{125}I]CXCL12 binding, and the other eight zinc complexes (of **12**, **14–19**, and **23**) showed less than 55% inhibition. The IC_{50} values of zinc complexes of **20–22**, **28**, and **29** were estimated to be 11, 8.3, 22, 40, and 52 nM, respectively. Zinc complexes of compounds containing a combination of cyclen and cyclam moieties, **20** and **21**, had remarkably potent IC_{50} values.

To form chelates with a copper(II) cation, CuCl_2 was added to solutions in PBS of **12–31**. The inhibition percentages of all the compounds at 1 μM against [^{125}I]CXCL12 binding are shown in Table 1. Copper complexes of **14** and **15** exhibited a significant increase in CXCR4 binding activity as compared to the corresponding copper-free compounds, a phenomenon which is also seen in the zinc chelates. These compounds have two cyclen moieties in the molecules, suggesting that zinc or copper complexation is critical for high binding activity. Compounds **16**, **17**, and **20–22** showed high binding affinities in metal-free states and zinc- and copper-complexed states, indicating that metallic complexation of the cyclam rings in these compounds is not necessary for high activity. The CXCR4 binding activity of the copper complex of **16** was previously reported.^[42] For compounds **17**, **22**, **23**, **28**, and **29**, copper complexation caused a significant decrease in binding activity compared to the corresponding copper-free compounds, whereas for compounds **14**, **15**, **18**, and **19**, copper complexation caused an increase in binding activity. This phenomenon may be due to the difference in ring sizes and structures of macrocycles, and was not observed upon zinc-complex formation. Inhibition at 0.1 μM of the copper complexes of **16** and **20–22**, which exhibited greater than 85% inhibition of [^{125}I]CXCL12 binding at 1 μM , are given in Table 1. The copper complexes of **16**, **20**, **21**, and **22** at 0.1 μM showed 39, 69, 88, and 39% inhibition, respectively, with the IC_{50} value of the copper complex of **21** estimated to be 16 nM.

Molecular modeling analysis of compound **21** and its zinc(II) and copper(II) complexes predicted that these complexes would form a stable coordinate conformation as shown in Figure 2. In general, zinc(II) complexes are predicted to adopt a tetrahedral conformation, while copper(II) complexes form a planar four coordinate/square conformation. The zinc(II) complex of **21** is predicted to have a tetrahedral conformation and the copper(II) complex a square planar conformation in both the cyclen and cyclam rings. The carboxyl group of either Asp171 or Asp262 in CXCR4 is thought to coordinate strongly with zinc ions but not copper ions in the complexes,^[41–43] and as a consequence, the zinc complex of **21** would bind more strongly than **21** or its copper complex. This order of binding

Table 1. CXCR4 binding activity of compounds 12–31 in the metal ion-free form, the zinc complex, and the copper complex.

Compd	Spacer	R ¹	R ²	Metal free			Zinc complex			Copper complex		
				Inhibition ^[a] [%] 1 μM	Inhibition ^[a] [%] 0.1 μM	IC ₅₀ ^[b] [nM]	Inhibition ^[a] [%] 1 μM	Inhibition ^[a] [%] 0.1 μM	IC ₅₀ ^[b] [nM]	Inhibition ^[a] [%] 1 μM	Inhibition ^[a] [%] 0.1 μM	IC ₅₀ ^[b] [nM]
12	<i>p</i> -xylene			0	n.d.	n.d.	83±2	24±5	n.d.	10±4	n.d.	n.d.
13	<i>m</i> -xylene			0	n.d.	n.d.	31±3	n.d.	n.d.	0	n.d.	n.d.
14	<i>p</i> -xylene			30±4	n.d.	n.d.	87±4	0	n.d.	60±2	n.d.	n.d.
15	<i>m</i> -xylene			33±2	n.d.	n.d.	94±1	13±6	n.d.	80±3	n.d.	n.d.
16	<i>p</i> -xylene			94±4	59±6	n.d.	97±5	28±3	n.d.	98±1	39±3	n.d.
17	<i>m</i> -xylene			95±3	49±9	n.d.	98±4	55±7	n.d.	75±1	n.d.	n.d.
18	<i>p</i> -xylene			32±0.7	n.d.	n.d.	97±6	0	n.d.	52±3	n.d.	n.d.
19	<i>m</i> -xylene			17±5	n.d.	n.d.	91±4	0	n.d.	22±6	n.d.	n.d.
20	<i>p</i> -xylene			89±3	62±3	n.d.	>100	79±1	11	>100	69±3	n.d.
21	<i>m</i> -xylene			89±3	66±3	n.d.	92±3	>100	8.3	>100	88±1	16
22	<i>p</i> -xylene			94±3	86±3	37	99±8	79±0.6	22	85±3	39±3	n.d.
23	<i>m</i> -xylene			58±8	n.d.	n.d.	90±17	37±0.3	n.d.	48±4	n.d.	n.d.
24	<i>p</i> -xylene			3±0.9	n.d.	n.d.	0	n.d.	n.d.	0	n.d.	n.d.
25	<i>m</i> -xylene			4±3	n.d.	n.d.	0	n.d.	n.d.	0	n.d.	n.d.
26	<i>p</i> -xylene			14±2	n.d.	n.d.	10±3	n.d.	n.d.	0	n.d.	n.d.
27	<i>m</i> -xylene			10±3	n.d.	n.d.	10±4	n.d.	n.d.	0	n.d.	n.d.
28	<i>p</i> -xylene			91±0.4	37±0.9	n.d.	97±4	>100	40	57±4	n.d.	n.d.
29	<i>m</i> -xylene			87±2	50±1	n.d.	>100	91±4	52	55±1	n.d.	n.d.
30	<i>p</i> -xylene			0	n.d.	n.d.	14±3	n.d.	n.d.	14±3	n.d.	n.d.
31	<i>m</i> -xylene			24±2	n.d.	n.d.	20±3	n.d.	n.d.	0	n.d.	n.d.
FC-131	<i>cyclo</i> -[D-Tyr-Arg-Arg-Nal-Gly-]			100	100	1.8	-	-	-	-	-	-

[a] CXCR4 binding activity was assessed based on inhibition of [¹²⁵I]CXCL12 binding to Jurkat cells. Percent inhibition for all compounds at 1 and 0.1 μM were calculated relative to the percent inhibition by FC131 (100%). [b] IC₅₀ values are the concentrations which correspond to 50% inhibition of [¹²⁵I]CXCL12 binding to Jurkat cells. All data are mean values ± SEM of at least three independent experiments. n.d. = not determined.

affinities is commonly seen for these compounds and their zinc(II) or copper(II) complexes.

We investigated the CXCR4 antagonistic activity of compound 22 and the zinc complexes of 20, 21, 22, and 28, all of

which possess strong CXCR4 binding activity. The CXCR4 antagonistic activity was assessed based on the inhibitory activity of the compounds against Ca²⁺ mobilization induced by CXCL12 stimulation through CXCR4 (figure S1 in the Support-




Figure 2. Structures calculated by molecular modeling of a) compound **21**, and its b) zinc and c) copper complexes. Atom color code: nitrogen = blue, carbon = gray, zinc = red, copper = light red.

ing Information). All of the tested compounds showed significant antagonistic activity at 1 μM .

The representative compounds **14**, **16**, **20–23**, **28**, and **29**, as well as their zinc chelates, were evaluated for anti-HIV activity. CXCR4 is the major co-receptor for the entry of T-cell-line-tropic (X4) HIV-1.^[10,11] Inhibitory activity against X4-HIV-1 (NL4-3 strain)-induced cytopathogenicity in MT-4 cells was assessed and is shown in Table 2.^[38] A correlation between CXCR4 bind-

tested compounds exhibited significant cytotoxicity (CC_{50} values $> 10 \mu\text{M}$; Table 2). Conversely, zinc complexes of **20**, **21**, **22**, and **28** did not exhibit significant anti-HIV activity against macrophage-tropic (R5) HIV-1 (NL(AD8) strain)-induced cytopathogenicity in PM-1 cells at concentrations below 10 μM . Since R5-HIV-1 strains use CCR5 instead of CXCR4 as the major co-receptor for entry, this suggests that these compounds do not bind CCR5 but rather are highly selective for CXCR4.

Table 2. Anti-HIV activity and cytotoxicity of representative compounds in the metal ion-free and zinc chelates.

Compd	Metal ion-free		Zinc chelate	
	$\text{EC}_{50}^{[a]}$ [nM]	$\text{CC}_{50}^{[b]}$ [μM]	$\text{EC}_{50}^{[a]}$ [nM]	$\text{CC}_{50}^{[b]}$ [μM]
14	200	> 10	200	> 10
16	21	> 10	8.2	> 10
20	38	> 10	39	> 10
21	50	> 10	36	> 10
22	93	> 10	48	> 10
23	290	> 10	220	> 10
28	36	> 10	56	> 10
29	130	> 10	42	> 10
FC131	93	> 10		
AZT	69	> 100		

[a] EC_{50} values are the concentrations corresponding to 50% protection from X4-HIV-1 (NL4-3 strain)-induced cytopathogenicity in MT-4 cells. [b] CC_{50} values are the concentrations at which the viability of MT-4 cells is reduced by 50%. All data are mean values from at least three independent experiments.

ing activity and anti-HIV activity was observed. For compound **16** and its zinc complex, anti-HIV activity was significantly stronger than CXCR4 binding activity, and for the zinc complexes of compounds **20–22**, the CXCR4 binding activity is two to four-times stronger than the anti-HIV activity. The anti-HIV activity of the zinc complex of **16** was the most potent ($\text{EC}_{50} = 8.2 \text{ nM}$). This is comparable to the anti-HIV activities of **16** and its zinc complex that were reported previously.^[20,22,42,43] The zinc complex of **21**, which was the most active compound in terms of CXCR4 binding activity, also exhibited potent anti-HIV activity ($\text{EC}_{50} = 36 \text{ nM}$).

Taken together, these results show that all of the compounds exhibiting CXCR4 binding activity also showed significant anti-HIV activity (EC_{50} values $< 300 \text{ nM}$), and none of the

Conclusions

The present study introduces a new class of low-molecular-weight CXCR4 antagonists and their zinc(II) or copper(II) complexes, which contain pyridyl or azamacrocyclic moieties with *p*-xylene or *m*-xylene spacers. These compounds demonstrated strong CXCR4 binding activity. Zinc complexes of **20** and **21**, which were the two most active compounds, contain cyclen and cyclam rings with *p*- and *m*-xylene spacers and exhibited remarkably potent IC_{50} values (11 and 8.3 nM, respectively). These compounds showed significant CXCR4 antagonistic activity, based on inhibitory activity against Ca^{2+} mobilization induced by CXCL12 stimulation through CXCR4, as well as potent anti-HIV activity, as assessed by protection from X4-HIV-1-induced cytopathogenicity in MT-4 cells. These results provide useful insights into the future design of novel CXCR4 antagonists, complementing information from other CXCR4 antagonists such as T140, FC131, and KRH-1636. Furthermore, these new compounds are useful for the development of therapeutic strategies for CXCR4-relevant diseases and chemical probes to study the biological activity of CXCR4.

Experimental Section

Chemistry

Compounds **12–17**, **20**, **21**, **24**, **25**, **27–29**, and **31** were synthesized as previously reported.^[20,22,37,40,41,44–47] Compounds **18**, **19**, **22**, **23**, **26**, and **30** were synthesized in the present study; details are provided in the Supporting Information. A representative compound, **18**, was synthesized by coupling *p*-dibromoxylene (1,4-bis-(bromomethyl)benzene) with tri-Boc-protected 1,4,7,10-tetraazacyclododecane, followed by treatment with trifluoroacetic acid and subsequent coupling with bis(pyridin-2-ylmethyl)amine. All crude compounds were purified by RP-HPLC and identified by FAB/ESI-

HRMS. Zinc(II) or copper(II) complex formation was accomplished by treatment of the above compounds with 10 equiv of $ZnCl_2$ or $CuCl_2$ in PBS. All zinc(II) or copper(II) complexes were characterized by chemical shifts of their methylene protons in 1H NMR analysis. The pyridyl zinc(II) complex was characterized previously,^[37] and zinc(II) or copper(II) complex formation with these macrocyclic compounds has been reported elsewhere.^[41,42,48,49] Detailed procedures and data are provided in the Supporting Information.

Biological assays

A CXCR4 binding assay for compounds, based on the inhibition of [^{125}I]CXCL12 binding to Jurkat cells, was performed as reported by Tanaka et al.^[38] CXCR4 antagonistic activity was evaluated as described by Ichiyama et al.^[27], measuring inhibitory activity against Ca^{2+} mobilization induced by CXCL12 stimulation in HOS cells expressing CXCR4. Anti-HIV activity was determined by inhibitory activity against X4-HIV-1(NL4-3)-induced cytopathogenicity in MT-4 cells as reported by Tanaka et al.^[38] An X4 HIV-1 infectious molecular clone (pNL4-3) was obtained from the AIDS Research and Reference Reagent Program. The virus NL4-3 was obtained from the culture supernatant of 293T cells transfected with pNL4-3.

Molecular modeling

Molecular modeling calculations were performed using Sybyl (version 7.0, Tripos). Energy minimization was performed using the Tripos force field and Gasteiger–Hückel charge parameters. The lowest energy conformation was obtained by random search methods.

Acknowledgements

T.T. and N.O. are supported by research fellowships for young scientists from the Japan Society for the Promotion of Science. This work was supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan, and Health and Labor Sciences Research Grants from the Japanese Ministry of Health, Labor, and Welfare. The authors thank Mr. Wu Honggui (Tokyo University of Science) for his assistance with the anti-HIV assay.

Keywords: azamacrocycles • Ca^{2+} mobilization • CXCR4 • HIV • structure–activity relationships

- [1] T. Nagasawa, H. Kikutani, T. Kishimoto, *Proc. Natl. Acad. Sci. USA* **1994**, *91*, 2305–2309.
- [2] C. C. Bleul, M. Farzan, H. Choe, C. Parolin, I. Clark-Lewis, J. Sodroski, T. A. Springer, *Nature* **1996**, *382*, 829–833.
- [3] E. Oberlin, A. Amara, F. Bachelier, C. Bessia, J. L. Virelizier, F. Arenzana-Seisdedos, O. Schwartz, J. M. Heard, I. Clark-Lewis, D. L. Legler, M. Loetscher, M. Baggiolini, B. Moser, *Nature* **1996**, *382*, 833–835.
- [4] K. Tashiro, H. Tada, R. Heilker, M. Shirozu, T. Nakano, T. Honjo, *Science* **1993**, *261*, 600–603.
- [5] C. C. Bleul, R. C. Fuhlbrigge, J. M. Casanovas, A. Aiuti, T. A. Springer, *J. Exp. Med.* **1996**, *184*, 1101–1109.
- [6] K. Tachibana, S. Hirota, H. Iizasa, H. Yoshida, K. Kawabata, Y. Kataoka, Y. Kitamura, K. Matsushima, N. Yoshida, S. Nishikawa, T. Kishimoto, T. Nagasawa, *Nature* **1998**, *393*, 591–594.
- [7] T. Nagasawa, S. Hirota, K. Tachibana, N. Takakura, S. Nishikawa, Y. Kitamura, N. Yoshida, H. Kikutani, T. Kishimoto, *Nature* **1996**, *382*, 635–638.
- [8] Y. Zhu, Y. Yu, X. C. Zhang, T. Nagasawa, J. Y. Wu, Y. Rao, *Nat. Neurosci.* **2002**, *5*, 719–720.
- [9] R. K. Stumm, C. Zhou, T. Ara, F. Lazarini, M. Dubois-Dalcq, T. Nagasawa, V. Holtt, S. Schulz, *J. Neurosci.* **2003**, *23*, 5123–5130.
- [10] H. K. Deng, R. Liu, W. Ellmeier, S. Choe, D. Unutmaz, M. Burkhart, P. D. Marzio, S. Marmon, R. E. Sutton, C. M. Hill, C. B. Davis, S. C. Peiper, T. J. Schall, D. R. Littman, N. R. Landau, *Nature* **1996**, *381*, 661–666.
- [11] Y. Feng, C. C. Broder, P. E. Kennedy, E. A. Berger, *Science* **1996**, *272*, 872–877.
- [12] T. Koshiba, R. Hosotani, Y. Miyamoto, J. Ida, S. Tsuji, S. Nakajima, M. Kawaguchi, H. Kobayashi, R. Doi, T. Hori, N. Fujii, M. Imamura, *Clin. Cancer Res.* **2000**, *6*, 3530–3535.
- [13] A. Müller, B. Homey, H. Soto, N. Ge, D. Catron, M. E. Buchanan, T. McClanahan, E. Murphy, W. Yuan, S. N. Wagner, J. L. Barrera, A. Mohar, E. Verstegui, A. Zlotnik, *Nature* **2001**, *410*, 50–56.
- [14] H. Tamamura, A. Hori, N. Kanzaki, K. Hiramatsu, M. Mizumoto, H. Nakashima, N. Yamamoto, A. Otaka, N. Fujii, *FEBS Lett.* **2003**, *550*, 79–83.
- [15] N. Tsukada, J. A. Burger, N. J. Zvaifler, T. J. Kipps, *Blood* **2002**, *99*, 1030–1037.
- [16] J. Juarez, K. F. Bradstock, D. J. Gottlieb, L. J. Bendall, *Leukemia* **2003**, *17*, 1294–1300.
- [17] T. Nanki, K. Hayashida, H. S. El-Gabalawy, S. Suson, K. Shi, H. J. Girschick, S. Yavuz, P. E. Lipsky, *J. Immunol.* **2000**, *165*, 6590–6598.
- [18] H. Tamamura, M. Fujisawa, K. Hiramatsu, M. Mizumoto, H. Nakashima, N. Yamamoto, A. Otaka, N. Fujii, *FEBS Lett.* **2004**, *569*, 99–104.
- [19] T. Murakami, T. Nakajima, Y. Koyanagi, K. Tachibana, N. Fujii, H. Tamamura, N. Toshida, M. Waki, A. Matsumoto, O. Yoshie, T. Kishimoto, N. Yamamoto, T. Nagasawa, *J. Exp. Med.* **1997**, *186*, 1389–1393.
- [20] D. Schols, S. Struyf, J. Van Damme, J. A. Este, G. Henson, E. DeClarcq, *J. Exp. Med.* **1997**, *186*, 1383–1388.
- [21] B. J. Doranz, K. Grovit-Ferbas, M. P. Sharron, S.-H. Mao, M. Bidwell Goetz, E. S. Daar, R. W. Doms, W. A. O'Brien, *J. Exp. Med.* **1997**, *186*, 1395–1400.
- [22] G. A. Donzella, D. Schols, S. W. Lin, J. A. Este, K. A. Nagashima, *Nat. Med.* **1998**, *4*, 72–76.
- [23] O. M. Z. Howard, J. J. Oppenheim, M. G. Hollingshead, J. M. Covey, J. Bigelow, J. J. McCormack, R. W. Buckheit, Jr., D. J. Clanton, J. A. Turpin, W. G. Rice, *J. Med. Chem.* **1998**, *41*, 2184–2193.
- [24] H. Tamamura, Y. Xu, T. Hattori, X. Zhang, R. Arakaki, K. Kanbara, A. Omagari, A. Otaka, T. Ibuka, N. Yamamoto, H. Nakashima, N. Fujii, *Biochem. Biophys. Res. Commun.* **1998**, *253*, 877–882.
- [25] H. Tamamura, A. Omagari, S. Oishi, T. Kanamoto, N. Yamamoto, S. C. Peiper, H. Nakashima, A. Otaka, N. Fujii, *Bioorg. Med. Chem. Lett.* **2000**, *10*, 2633–2637.
- [26] N. Fujii, S. Oishi, K. Hiramatsu, T. Araki, S. Ueda, H. Tamamura, A. Otaka, S. Kusano, S. Terakubo, H. Nakashima, J. A. Broach, J. O. Trent, Z. Wang, S. C. Peiper, *Angew. Chem.* **2003**, *115*, 3373–3375; *Angew. Chem. Int. Ed.* **2003**, *42*, 3251–3253.
- [27] K. Ichiyama, S. Yokoyama-Kumakura, Y. Tanaka, R. Tanaka, K. Hirose, K. Bannai, T. Edamatsu, M. Yanaka, Y. Niitani, N. Miyano-Kurosaki, H. Takaku, Y. Koyanagi, N. Yamamoto, *Proc. Natl. Acad. Sci. USA* **2003**, *100*, 4185–4190.
- [28] H. Tamamura, N. Fujii, *Curr. Drug Targets-Infectious Disorders* **2004**, *4*, 103–110.
- [29] H. Tamamura, K. Hiramatsu, S. Ueda, Z. Wang, S. Kusano, S. Terakubo, J. O. Trent, S. C. Peiper, N. Yamamoto, H. Nakashima, A. Otaka, N. Fujii, *J. Med. Chem.* **2005**, *48*, 380–391.
- [30] H. Tamamura, T. Araki, S. Ueda, Z. Wang, S. Oishi, A. Esaka, J. O. Trent, H. Nakashima, N. Yamamoto, S. C. Peiper, A. Otaka, N. Fujii, *J. Med. Chem.* **2005**, *48*, 3280–3289.
- [31] G. C. Valks, G. McRobbie, E. A. Lewis, T. J. Hubin, T. M. Hunter, P. J. Sadler, C. Pannecoque, E. De Clercq, S. J. Archibald, *J. Med. Chem.* **2006**, *49*, 6162–6165.
- [32] W. Zhan, Z. Liang, A. Zhu, S. Kurtkaya, H. Shim, J. P. Snyder, D. C. Liotta, *J. Med. Chem.* **2007**, *50*, 5655–5664.
- [33] A. Khan, G. Nicholson, J. Greenman, L. Madden, G. McRobbie, C. Pannecoque, E. De Clercq, R. Ullom, D. L. Maples, R. D. Maples, J. D. Silversides, T. J. Hubin, S. J. Archibald, *J. Am. Chem. Soc.* **2009**, *131*, 3416–3417.
- [34] G. J. Bridger, R. T. Skerlj, P. E. Hernandez-Abad, D. E. Bogucki, Z. Wang, Y. Zhou, S. Nan, E. M. Boehringer, T. Wilson, J. Crawford, M. Metz, S. Hatse, K. Princen, E. De Clercq, D. Schols, *J. Med. Chem.* **2010**, *53*, 1250–1260.

- [35] R. T. Skerlj, G. J. Bridger, A. Kaller, E. J. McEachern, J. B. Crawford, Y. Zhou, B. Atsma, J. Langille, S. Nan, D. Veale, T. Wilson, C. Harwig, S. Hatse, K. Princen, E. De Clercq, D. Schols, *J. Med. Chem.* **2010**, *53*, 3376–3388.
- [36] M. Takenaga, H. Tamamura, K. Hiramatsu, N. Nakamura, Y. Yamaguchi, A. Kitagawa, S. Kawai, H. Nakashima, N. Fujii, R. Igarashi, *Biochem. Biophys. Res. Commun.* **2004**, *320*, 226–232.
- [37] H. Tamamura, A. Ojida, T. Ogawa, H. Tsutsumi, H. Masuno, H. Nakashima, N. Yamamoto, I. Hamachi, N. Fujii, *J. Med. Chem.* **2006**, *49*, 3412–3415.
- [38] T. Tanaka, H. Tsutsumi, W. Nomura, Y. Tanabe, N. Ohashi, A. Esaka, C. Ochiai, J. Sato, K. Itotani, T. Murakami, K. Ohba, N. Yamamoto, N. Fujii, H. Tamamura, *Org. Biomol. Chem.* **2008**, *6*, 4374–4377.
- [39] G. J. Bridger, R. T. Skerlj, D. Thornton, S. Padmanabhan, S. A. Martellucci, G. W. Henson, M. J. Abrams, N. Yamamoto, K. De Vreese, R. Pauwels, E. De Clercq, *J. Med. Chem.* **1995**, *38*, 366–378.
- [40] G. J. Bridger, R. T. Skerlj, S. Padmanabhan, S. A. Martellucci, G. W. Henson, M. J. Abrams, H. C. Joao, M. Witvrouw, K. De Vreese, R. Pauwels, E. De Clercq, *J. Med. Chem.* **1996**, *39*, 109–119.
- [41] Y. Inouye, T. Kanamori, T. Yoshida, T. Koike, M. Shionoya, H. Fujioka, E. Kimura, *Biol. Pharm. Bull.* **1996**, *19*, 456–458.
- [42] L. O. Gerlach, J. S. Jakobsen, K. P. Jensen, M. R. Rosenkilde, R. T. Skerlj, U. Ryde, G. J. Bridger, T. W. Schwartz, *Biochemistry* **2003**, *42*, 710–717.
- [43] H. F. Egberink, E. De Clercq, A. L. Van Vliet, J. Balzarini, G. J. Bridger, G. Henson, M. C. Horzinek, D. Schols, *J. Virol.* **1999**, *73*, 6346–6352.
- [44] M. Le Baccon, F. Chuburu, L. Toupet, H. Handel, M. Soibinet, I. De-champs-Olivier, J.-P. Barbier, M. Aplincourt, *New J. Chem.* **2001**, *25*, 1168–1174.
- [45] B. Antonioli, D. J. Bray, J. K. Clegg, K. Gloe, K. Gloe, O. Kataeva, L. F. Lindoy, J. C. McMurtrie, P. J. Steel, C. J. Sumbly, M. Wenzel, *Dalton Trans.* **2006**, 4783–4794.
- [46] S. P. Foxon, D. Utz, J. Astner, S. Schindler, F. Thaler, F. W. Heinemann, G. Liehr, J. Mukherjee, V. Balamurugan, D. Ghosh, R. Mukherjee, *Dalton Trans.* **2004**, 2321–2328.
- [47] S. Mandal, F. Lloret, R. Mukherjee, *Inorg. Chim. Acta* **2009**, *362*, 27–37.
- [48] M. Soibinet, I. De'champs-Olivier, E. Guillon, J.-P. Barbier, M. Aplincourt, F. Chuburu, M. Le Baccon, H. Handel, *Eur. J. Inorg. Chem.* **2003**, 1984–1994.
- [49] R. W. Hay, M. T. Tarafder, *Transition Met. Chem.* **1990**, *15*, 490–492.

Received: December 19, 2010

Published online on February 10, 2011

DOI: 10.1002/cbic.201000670

Synthetic Caged DAG-lactones for Photochemically Controlled Activation of Protein Kinase C

Wataru Nomura,^[a] Tetsuo Narumi,^[a] Nami Ohashi,^[a] Yuki Serizawa,^[a] Nancy E. Lewin,^[b] Peter M. Blumberg,^[b] Toshiaki Furuta,^[a, c] and Hirokazu Tamamura*^[a]


The signal transduction pathways associated with interactions with small organic molecules attract great interest in the field of chemical biology. To study the action of bioactive compounds in detail, it is necessary to eliminate the signaling complexity caused by multiple combined effects. The development of "caged" compounds, which are not active when the pharmacophore is blocked by a photoactivatable moiety, has been a powerful tool with which to approach this problem. Triggered by photoirradiation to a limited area in the cell, the specific effects of the ligand in that location can then be observed over time. Several strategies for "caging" molecules have been developed and each approach has its own advantages.^[1]

The protein kinase C (PKC) isoforms play pivotal roles in physiological responses to growth factors and oxidative stress mediated through the endogenous second messenger 1,2-diacylglycerol (DAG). These responses regulate numerous cellular processes,^[2] including proliferation,^[3] differentiation,^[4] migration,^[5] and apoptosis.^[6] The tumor-promoting phorbol esters, potent analogues of DAG, have provided a convenient probe of PKC function. Ligand binding to the C1b domain in PKC leads to its membrane translocation. The translocation of PKC is of central importance for its function because the localization of PKC determines the substrates to which it has access.^[7] Despite the complex regulatory mechanisms of PKC activation, considerable progress in understanding isozyme-specific functions has been made.^[8] Development of ligands with high specificities for PKC isozymes has been a critical issue in the medicinal field.^[9a–b] Enhancement of the understanding of targets and signaling pathways would provide important insights contributing to this effort.

As high-affinity ligands for PKC, DAG-lactones have established the importance of the pharmacophore triad of two carbonyl groups (*sn*-1 and *sn*-2) and the hydroxy group being

maintained intact.^[8] In this study, we have utilized coumarin-based "caging" molecules including 6-bromo-7-hydroxycoumarin (Bhc)^[10] and 6-bromo-7-methoxycoumarin (Bmc)^[11] to block the binding of DAG-lactones to PKC δ . The caged protecting groups are attached to the primary alcohol, which is an important DAG-lactone pharmacophore. Photolytic uncaging of the blocked DAG-lactone then provides a means of driving PKC activation within the cell at desired specific locations and times. An approach previously used to achieve this goal has been the use of caged diacylglycerols.^[14,12] DAG-lactones have several potential advantages. Extensive medical chemistry investigations have yielded DAG-lactones with substantially enhanced affinities, a range of physicochemical properties, and interesting biological selectivities with regard to diacylglycerol targets.^[8]

The DAG-lactones have been developed as ligands for PKC isozymes with low-nanomolar binding affinities by a combination of pharmacophore- and receptor-guided approaches based on the structure of the physiological second messenger DAG (Scheme 1).^[8] The DAG-lactones were designed by the



Scheme 1. A) The *sn*-2 binding model of DAG-lactones to the PKC δ C1b domain and membrane. B) Structures of the DAG-lactones 1, 2, and 4. a) 2-Propylpentanoyl chloride, pyridine, CH₂Cl₂, 24%.

pharmacophore-guided approach based on the geometries of bioequivalent pharmacophores present in DAG and in phorbol esters.^[13] In the DAG-lactone structure, the glycerol backbone was constrained to a γ -lactone ring to reduce the entropic penalty associated with DAG binding. In binding to PKC, the linear or branched acyl (R¹) or α -alkylidene (R²) chains contribute to optimized hydrophobic interactions with a group of conserved hydrophobic amino acids located on the top half of the C1 domain. There are two competing binding modes (*sn*-1 and *sn*-2), depending on which carbonyl group is directly involved in binding to the protein (Scheme 1A). In general, it

[a] Dr. W. Nomura, Dr. T. Narumi, N. Ohashi, Y. Serizawa, Prof. T. Furuta, Prof. H. Tamamura
Department of Medicinal Chemistry
Institute of Biomaterials and Bioengineering
Tokyo Medical and Dental University
2-3-10 Kandasurugadai, Chiyoda-ku, Tokyo 101-0062 (Japan)
Fax: (+81) 3-5280-8039
E-mail: tamamura.mr@tmd.ac.jp

[b] N. E. Lewin, Dr. P. M. Blumberg
Laboratory of Cancer Biology and Genetics, Center for Cancer Research
National Cancer Institute, National Institutes of Health
Bethesda, Maryland 20892 (USA)

[c] Prof. T. Furuta
Faculty of Science, Toho University
2-2-1 Miyama, Funabashi, Chiba 274-8510 (Japan)

Supporting information for this article is available on the WWW under <http://dx.doi.org/10.1002/cbic.201000670>.

has been found that DAG favors *sn*-1 binding, whereas the corresponding DAG-lactone analogues favor *sn*-2 binding.^[8] In this study, three representative DAG-lactones—1, 2, and 4 (Scheme 1B)—were investigated. Compound 1 had previously been reported as part of a branched α -alkylidene series that provided the most potent α -alkylidene analogues.^[9,14] Comparison of the binding affinities of the stereoisomers showed that the *Z* isomer of lactone 1 had a higher affinity for PKC δ than the *E* isomer. The *Z* isomer of compound 1 was therefore purified by flash chromatography and utilized for experiments. Compound 2 had also previously been synthesized to assess the role of a flexible decanoic acid chain at the acyl chain position (R¹).^[9a] Compound 4 was synthesized as a compound with a branched chain as an acyloxy moiety and an isopropylidene system as an α -alkylidene group; a similar compound with a more branched acyloxy moiety has been reported.^[15] The lactones 2 and 4 each contain an isopropylidene group at the α -alkylidene position, which has been identified as one of the principal determinants for control of biological activity. The effect of the acyl group on the isozyme specificity of the DAG-lactones has been investigated with a series of compounds.

The binding affinities of the DAG-lactones were determined as described previously.^[16] The K_i values of the compounds were determined as 8.4 ± 2.9 , 6.5 ± 0.8 , and 22 ± 1.6 nM (mean \pm SEM) for 1, 2, and 4, respectively. The binding affinities of 1 and 2 were compatible with those in the previous reports^[9a,15b] (2.3 and 15.9 nM, respectively), whereas that of 4 was weaker than those of the related compounds. It has been reported that branched chains interfere with the interaction with the hydrophobic surface of the C1b domain in the *sn*-2 binding mode of DAG-lactones. As reported previously, the acyl and α -alkylidene moieties affect PKC δ translocation caused by ligand binding. To reveal the translocation caused by the synthesized DAG-lactones, CHO-K1 cells expressing a PKC δ -EGFP fusion construct were prepared and the PKC δ -EGFP was visualized by confocal microscopy as a function of time after ligand addition (Figure 1A–C). Compound 1 at 10 μ M did not cause translocation of PKC δ even 30 min after addition (data not shown). Compound 2 caused rapid translocation, requiring 5 min for complete translocation. Compound 4 caused less complete and slower translocation, perhaps reflecting its weaker potency. As described for other DAG-lactones, translocation was predominantly to internal membrane compartments (nuclear membrane, mitochondria, and other cellular organelles).^[17] From these studies, compound 2 was selected as the most suitable for photoactivation analysis with the aid of caged protecting groups.

To study PKC δ activation by photolysis of ligands, caged compounds were synthesized as depicted in Scheme 1B. As caging moieties, (6-bromo-7-hydroxycoumarin-4-yl)methoxycarbonyl (Bhcmoc) and (6-bromo-7-methoxycoumarin-4-yl)methoxycarbonyl (Bmcmoc) were utilized. Several caged compounds based on these caging moieties have been reported previously.^[11c] As one of the most commonly used classes of structures for the protection of phosphate, amine, and carbonyl functional groups, coumarin-based protecting groups including MCM,^[18] HCM (and ACM),^[19] DMCM,^[20] BCMCM,^[21] DMACM




Figure 1. Translocation of PKC δ caused by compounds 1, 2, and 4. A)–C) Time-dependent translocation of compounds 1, 2, and 4, respectively (0, 1, 5, and 10 min after addition of compounds). The final concentration of the compounds was 10 μ M. The scale bar indicates 50 μ m.

(and DEACM),^[22] and Bhc^[10] have been successfully developed. Given its critical role in forming two of the three hydrogen bonds driving binding of the DAG-lactone to the binding pocket of the C1 domain, the hydroxy group of the DAG-lactone was the obvious site for addition of the coumarin-based protecting group in order to disrupt binding (Scheme 1A).

The function of the Bhc- and Bmc-protected DAG-lactones 10 and 11 as “phototriggers” (Figure 2A) was evaluated in terms of several parameters. Firstly, the UV spectra of the compounds were determined (Figure 2B). The compounds showed clear absorbance originating from the caged moiety. The absorbance maxima for Bhc-2 and Bmc-2 were 377 and 329 nm, respectively. Next, photolysis was performed with the aid of a photochemical lamp (RPR3500 Å). The breakdown of the caged compounds and the production of the uncaged compounds were monitored by HPLC and the extent of the reaction was calculated from the peak areas, which were determined as a function of irradiation time (Figure 2C). Quantitative production of the parent compound 2 was successfully observed. The preferred environment of the caging groups for photolysis is thus hydrophilic, accounting for the superiority of the Bhc group over the Bmc group in photolysis efficiency (Table S1 in the Supporting Information). The photochemical properties of Bmc-1 and Bmc-4 were also assessed. The results support the view that compound 2 is suitable for photoactivation analysis (Figures S1, S2, and Table S2).

To evaluate the binding affinities of the caged compounds, competitive binding analysis to PKC δ was performed as described previously.^[16] The results indicated that the caged compounds, in which the hydroxy group was protected, showed decreases in binding affinity of more than 100-fold (Table S1). The measured binding affinities of Bhc-2 (10) and Bmc-2 (11) to PKC δ were 431 and 940 nM, respectively. For comparison, compound 2 without the blocking group had an affinity of 6.5 nM. In the proposed binding mode of the DAG-lactones to




Figure 2. Structures of the caged compounds Bhc-2 (10) and Bmc-2 (11) and their photochemical properties. A) Representation of photochemical cleavage of the caged compounds 2. B) UV spectra of 2 (gray line), Bhc-2 (thick black line), and Bmc-2 (thin black line). C) Plots of one-photon photolysis experiments. The plots show Bhc-2 remaining (●), Bhc-2 product (▼), Bmc-2 remaining (■), and Bmc-2 product (▲).

PKC, the carbonyl oxygen of the DAG-lactone interacts with Gly253 of PKC δ , and the hydrogen and oxygen of the hydroxy group interact with Leu251 and Thr242, respectively. In the *sn*-2 binding mode, which is known to be preferred by DAG-lactones, the acyl group is proposed to interact with the lipid bilayer of the cellular membranes. In this mode, the caged hydroxy group cannot interact with Leu 251 or Thr242. The caged DAG-lactones thus successfully displayed "loss of function" in binding, a requisite property of caged compounds. To examine the effects on translocation of PKC δ in mammalian cells, the caged compounds Bhc-2 and Bmc-2 were added to medium at 10 μ M, a concentration at which compound 2 caused rapid translocation. Consistently with their loss of binding affinity for PKC δ , as shown by the *in vitro* analysis, the caged compounds failed to induce PKC δ translocation, confirming that the activation of PKC δ by compound 2 is successfully retarded by caging (Figure S3). The behavior of Bhc-2 (10) upon photolysis was also evaluated under the confocal micro-

scope. Of the synthetic compounds in this study, Bhc-2 was most suitable for the purpose in terms of the efficiency of the photolysis reaction and rapid translocation of PKC δ . Translocation and reactivation of kinase activity by uncaged Bhc-2 were confirmed (Figure S4).

To elucidate PKC-related signal transduction by stimulation of ligand binding, spatially and temporally controlled activation is desirable. To assess this point, photoirradiation at a limited region of interest (ROI) in the cell was performed. Because photolysis will only unblock caged ligand located in the irradiated region, the response following the activation should reflect this time- and location-dependent generation of active ligand. As shown in Figure 3, translocation was observed at




Figure 3. Translocation activated by photolysis of Bhc-2 (10). The region of interest (ROI) is limited to the inside of the circle [orange in (A)]. The panels show the translocation of EGFP-PKC δ fusion protein in a time-course as follows: A) before photoirradiation, B) 2 min, C) 5 min, and D) 10 min after photoirradiation. The image in each panel shows EGFP fluorescence. The scale bar indicates 20 μ m. The detailed pictures with pseudocolors are given in Figure S5. E) Fluorescent intensity mapped along the orange bar from (i) to (ii) in the panel. The thin and thick lines show the intensity at 0 and 10 min of photoirradiation, respectively.

10 min after photoirradiation of Bhc-2 (10). The pattern of sub-cellular localization was similar to that of compound 2 as shown in Figure 1. However, the time-course of translocation was dramatically slower, taking 10 min, in contrast with the rapid response seen upon addition of compound 2. We conclude that the photolysis of compound Bhc-2 was successful, in that translocation was observed. The slow kinetics are consistent with the concentration of the released DAG-lactone 2 being relatively low, which would be expected because the photolysis reaction occurred in the limited area of the ROI. Additionally, the cells around the ROI target cell also showed translocation of PKC δ . This effect might be caused by the release of uncaged compound and its reuptake by surrounding cells. The DAG-lactones are highly lipophilic, with their computed log*P* values ranging from 3 to 5. This property allows DAG-lactones to complete the hydrophobic surface of the C1b domain of PKC δ and to interact with the lipid bilayer of the membrane. However, the lipophilicity of the DAG-lactones also

allows the compounds to permeate through membranes and to be released back into the medium, making them available for reuptake.


It has been shown that patterns and kinetics of translocation of activated PKC δ depend on the lipophilicity and side-chain structures of DAG-lactones.^[8] For compound **2**, it was possible that the translocation caused is to the Golgi apparatus, because the activated PKC δ is accumulated to the perinuclear region. To confirm the translocation to the Golgi apparatus, cellular staining by BODIPY TR ceramide was performed on CHO-K1 cells expressing PKC δ -EGFP. Compound **2** was added to these cells at 10 μ M. After 10 min of compound addition, the amount of PKC δ that had colocalized with Golgi apparatus was increased (Figure S6). In the next study to determine the differences in translocation between cell lines, A549 and HeLa were utilized in addition to CHO-K1 cells. As shown in Figure 4, photoirradiation induced translocation of PKC δ in all cell lines. In comparison with the stimulation by compound **2**, translocation was modest because of the low concentration of released compound **2** as discussed above. Of the cell types examined, HeLa cells showed most distinctive translocation to Golgi apparatus and nuclear membrane.

In this study, the Bhc- and Bmc-caged DAG-lactones were prepared and evaluated in terms of photochemical control of PKC activation. DAG-lactone binding to PKC δ in mammalian cells was successfully controlled through photoirradiation. Derivatization at the DAG-lactone hydroxy group was shown to be very effective for diminishing affinity towards PKC. Photoactivation limited to the ROI was successfully regulated. However, there remained effects on other cells near the cells of interest, and this needs to be addressed in future studies. Development of more precise photochemical control methodology will be needed to address the signaling mechanism related to PKC δ in a single cell or at a single location within a single cell. Nonetheless, these results indicate the potential of this approach for studying PKC function.^[1b,c]

Acknowledgements

The authors thank Professor Kazunari Akiyoshi (Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University) for assistance with the laser microscopy. This study was supported in part by the Naito Foundation for Science (to W.N.) and in part by the Intramural Research Program of the NIH, Center for Cancer Research, National Cancer Institute. N.O. is supported by the Japan Society for Promotion of Science.

Figure 4. Observation of translocation of activated PKC δ within the Golgi-stained cells by photolysis of Bhc-2 (**10**) in ROI. The cells are: A) CHO-K1, C) A549, and E) HeLa. The ROI is limited to the inside of the orange circles. Each set of cell images shows before photoirradiation (top) and 10 min after (bottom); EGFP-PKC δ , staining by BODIPY TR ceramide, merged image, and differential interference contrast (DIC) from left to right. The scale bars indicate 20 μ m. B), D), and F) Fluorescent intensities mapped along the orange bars from (i) to (ii) in the panels. The thin and thick lines show the intensity at 0 and 10 min of photoirradiation, respectively.



Keywords: cage compounds · diacylglycerol · drug design · enzymes · proteins

- [1] a) G. Dormán, G. D. Prestwich, *Trends Biotechnol.* **2000**, *18*, 64–77; b) G. Mayer, A. Heckel, *Angew. Chem.* **2006**, *118*, 5020–5042; *Angew. Chem. Int. Ed.* **2006**, *45*, 4900–4921; c) H.-M. Lee, D. R. Larson, D. S. Lawrence, *ACS Chem. Biol.* **2009**, *4*, 409–427; d) E. J. Quann, E. Merino, T. Furuta, M. Huse, *Nat. Immunol.* **2009**, *10*, 627–637.
- [2] a) Y. Nishizuka, *Science* **1992**, *258*, 607–614; b) A. C. Newton, *J. Biol. Chem.* **1995**, *270*, 28495–28498.
- [3] T. Watanabe, Y. Ono, Y. Taniyama, K. Hazama, K. Igarashi, K. Ogita, U. Kikawa, Y. Nishizuka, *Proc. Natl. Acad. Sci. USA* **1992**, *89*, 10159–10163.
- [4] H. Mischak, J. H. Pierce, J. Goodnight, M. G. Kazanietz, P. M. Blumberg, J. F. Mushinski, *J. Biol. Chem.* **1993**, *268*, 20110–20115.
- [5] C. Li, E. Wernig, M. Leitges, Y. Hu, Q. Xu, *FASEB J.* **2003**, *17*, 2106–2108.
- [6] a) T. Ghayur, M. Hugunin, R. V. Talanian, S. Ratnofsky, C. Quinlan, Y. Emoto, P. Pandey, R. Datta, Y. Huang, S. Kharbanda, H. Allen, R. Kamen, W. Wong, D. Kufe, *J. Exp. Med.* **1996**, *184*, 2399–2404; b) D. L. Alkon, M.-K. Sun, T. J. Nelson, *Trends Pharmacol. Sci.* **2007**, *28*, 51–60.
- [7] Q. J. Wang, *Trends Pharmacol. Sci.* **2006**, *27*, 317–323.
- [8] V. E. Marquez, P. M. Blumberg, *Acc. Chem. Res.* **2003**, *36*, 434–443.
- [9] a) K. Nacro, B. Bienfait, J. Lee, K.-C. Han, J.-H. Kang, S. Benzaria, N. E. Lewin, D. K. Bhattacharyya, P. M. Blumberg, V. E. Marquez, *J. Med. Chem.* **2000**, *43*, 921–944; b) H. Tamamura, B. Beinfait, K. Nacro, N. E. Lewin, P. M. Blumberg, V. E. Marquez, *J. Med. Chem.* **2000**, *43*, 3210–3217.
- [10] a) T. Furuta, S. S.-H. Wang, J. L. Dantzker, T. M. Dore, W. J. Bybee, E. M. Callaway, W. Denk, R. Y. Tsien, *Proc. Natl. Acad. Sci. USA* **1999**, *96*, 1193–1200; b) H. Ando, T. Furuta, R. Y. Tsien, H. Okamoto, *Nat. Genet.* **2001**, *28*, 317–325; c) H. J. Montgomery, B. Perdicakis, D. Fishlock, G. A. Lajoie, E. Jervis, J. G. Guillemette, *Bioorg. Med. Chem.* **2002**, *10*, 1919–1927; d) W. Lin, D. S. Lawrence, *J. Org. Chem.* **2002**, *67*, 2723–2726; e) M. Lu, O. D. Fedoryak, B. R. Moister, T. M. Dore, *Org. Lett.* **2003**, *5*, 2119–2122; f) A. Z. Suzuki, T. Watanabe, M. Kawamoto, K. Nishiyama, H. Yamashita, M. Ishii, M. Iwamura, T. Furuta, *Org. Lett.* **2003**, *5*, 4867–4870.
- [11] T. Furuta, T. Watanabe, S. Tanabe, J. Sakyō, C. Matsuba, *Org. Lett.* **2007**, *9*, 4717–4720.
- [12] a) X. P. Huang, R. Sreekumar, J. R. Patel, J. W. Walker, *Biophys. J.* **1996**, *70*, 2448–2457; b) V. G. Robu, E. S. Pfeiffer, S. L. Robia, R. C. Balijepalli, Y. Pi, T. J. Kamp, J. W. Walker, *J. Biol. Chem.* **2003**, *278*, 48154–48161.
- [13] a) Y. Kishi, R. R. Rando, *Acc. Chem. Res.* **1998**, *31*, 163–172; b) P. A. Wender, C. M. Cribbs, K. F. Koehler, N. A. Sharkey, C. L. Herald, Y. Kamano, G. R. Petit, P. M. Blumberg, *Proc. Natl. Acad. Sci. USA* **1998**, *95*, 7197–7201; c) S. Wang, G. W. A. Milne, M. C. Nicklaus, V. E. Marquez, J. Lee, P. M. Blumberg, *J. Med. Chem.* **1994**, *37*, 1326–1338.
- [14] a) H. Tamamura, D. M. Sugano, N. E. Lewin, P. M. Blumberg, V. E. Marquez, *J. Med. Chem.* **2004**, *47*, 644–655; b) K. Malolanarasimhan, N. Keddi, D. M. Sigano, J. A. Kelley, C. C. Lai, N. E. Lewin, R. J. Surawski, V. A. Pavlyukovets, S. H. Garfield, S. Wincovitch, P. M. Blumberg, V. E. Marquez, *J. Med. Chem.* **2007**, *50*, 962–978.
- [15] D. M. Sigano, M. L. Peach, K. Nacro, Y. Choi, N. E. Lewin, M. C. Nicklaus, P. M. Blumberg, V. E. Marquez, *J. Med. Chem.* **2003**, *46*, 1571–1579.
- [16] a) N. A. Sharkey, P. M. Blumberg, *Cancer Res.* **1985**, *45*, 19–24; b) M. G. Kazanietz, K. W. Krausz, P. M. Blumberg, *J. Biol. Chem.* **1992**, *267*, 20878–20886.
- [17] L. Li, P. S. Lorenzo, K. Bogi, P. M. Blumberg, S. H. Yupsa, *Mol. Cell. Biol.* **1999**, *19*, 8547–8558.
- [18] a) T. Furuta, H. Torigai, M. Sugimoto, M. Iwamura, *J. Org. Chem.* **1995**, *60*, 3953–3956; b) B. Schade, V. Hagen, R. Schmidt, R. Herbrich, E. Krause, T. Eckardt, J. Bendig, *J. Org. Chem.* **1999**, *64*, 9109–9117.
- [19] a) T. Furuta, A. Momotake, M. Sugimoto, M. Hatayama, M. Iwamura, *Biochem. Biophys. Res. Commun.* **1996**, *228*, 193–198; b) T. Furuta, M. Iwamura, *Methods Enzymol.* **1998**, *291*, 50–63.
- [20] T. Eckardt, V. Hagen, B. Schade, R. Schmidt, C. Schweitzer, J. Bendig, *J. Org. Chem.* **2002**, *67*, 703–710.
- [21] a) V. Hagen, J. Bendig, S. Frings, T. Eckardt, S. Helm, D. Reuter, U. B. Kaupp, *Angew. Chem.* **2001**, *113*, 1077–1080; *Angew. Chem. Int. Ed.* **2001**, *40*, 1045–1048; b) V. Hagen, S. Frings, J. Bendig, D. Lorenz, B. Wiesner, U. B. Kaupp, *Angew. Chem.* **2002**, *114*, 3775–3777; *Angew. Chem. Int. Ed.* **2002**, *41*, 3625–3628.
- [22] a) D. Geißler, W. Kresse, B. Wiesner, J. Bendig, H. Kettenmann, V. Hagen, *ChemBioChem* **2003**, *4*, 162–170; b) V. Hagen, S. Frings, B. Wiesner, S. Helm, U. B. Kaupp, J. Bendig, *ChemBioChem* **2003**, *4*, 434–442.

Received: November 8, 2010



Published online on ■■■■■, 0000

COMMUNICATIONS

W. Nomura, T. Narumi, N. Ohashi,
Y. Serizawa, N. E. Lewin, P. M. Blumberg,
T. Furuta, H. Tamamura*



**Synthetic Caged DAG-lactones for
Photochemically Controlled Activation
of Protein Kinase C**



Switching on kinases: Synthetic caged DAG-lactones have been developed and showed decreases of two orders of magnitude, relative to the corresponding parent compounds, in their binding affinities towards PKC. The caged compounds had no effect on the translocation of PKC until after photoactivation. This approach is a potentially powerful tool for probing the PKC signaling cascade.

Fluorescent-Responsive Synthetic C1b Domains of Protein Kinase C δ as Reporters of Specific High-Affinity Ligand Binding

Nami Ohashi,[†] Wataru Nomura,^{*,†} Tetsuo Narumi,[†] Nancy E. Lewin,[‡] Kyoko Itotani,[†] Peter M. Blumberg,[‡] and Hirokazu Tamamura^{*,†}

Department of Medicinal Chemistry, Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, 2-3-10 Kandasurugadai, Chiyoda-ku, Tokyo 101-0062, Japan, and Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, United States. Received September 18, 2010; Revised Manuscript Received December 3, 2010

Protein kinase C (PKC) is a critical cell signaling pathway involved in many disorders such as cancer and Alzheimer-type dementia. To date, evaluation of PKC ligand binding affinity has been performed by competitive studies against radiolabeled probes that are problematic for high-throughput screening. In the present study, we have developed a fluorescent-based binding assay system for identifying ligands that target the PKC ligand binding domain (C1 domain). An environmentally sensitive fluorescent dye (solvatochromic fluorophore), which has been used in multiple applications to assess protein-binding interactions, was inserted in proximity to the binding pocket of a novel PKC δ C1b domain. These resultant fluorescent-labeled δ C1b domain analogues underwent a significant change in fluorescent intensity upon ligand binding, and we further demonstrate that the fluorescent δ C1b domain analogues can be used to evaluate ligand binding affinity.

INTRODUCTION

Protein kinase C (PKC) is a family of serine/threonine protein kinases comprising 11 isozymes divided into three subclasses, termed conventional (α , β_{VII} , γ), novel (δ , ϵ , η , θ), and atypical (ζ , λ , ι). Their classification is based on their essential structures and affinities for regulatory factors such as diacylglycerol (DAG) and calcium that bind to the C1 and C2 domains, respectively, of PKC. PKC plays a pivotal role in physiological responses to growth factors, oxidative stress, and tumor promoters (phorbol esters). These responses regulate numerous cellular processes (1, 2), including proliferation (3), differentiation (4), migration (5), and apoptosis (6, 7). The extensive involvement of PKC in both normal physiology and in numerous disorders has caused PKC to emerge as an important therapeutic target (8–10). Since PKC activation is regulated through the binding of ligands to its C1 domains, development of useful ligands targeted to the C1 domains has been of intense interest for medicinal chemists. Various synthetic PKC ligands based on γ -lactone templates have been developed and evaluated (11–13). On the other hand, since structures of many of the potent, naturally occurring PKC ligands such as the phorbol esters are highly complex, it has been difficult to extensively probe their structure–activity relationships. Much opportunity therefore remains for the development of ligands optimized for isozyme selectivity or other properties. Fluorescent-based methods possess many advantages for high-throughput screening. Especially, utilization of environmentally sensitive fluorophores is suitable for high-throughput techniques because washing steps are not generally required. Fluorophores often respond to the environmental changes in hydrophobic/hydrophilic states associated with the conformational changes of proteins accompanying ligand binding. Several screening methods based on fluorescent-modified

peptides, e.g., an IP₃ sensor, have been developed to date (14–17). In this study, fluorescent-labeled C1b domains of PKC δ utilizing a solvatochromic dye as a sensor of ligand binding were designed and synthesized as efficient screening tools to evaluate ligand binding and to explore novel PKC pharmacophores.

EXPERIMENTAL PROCEDURES

General Methods. For chromatography, Wakogel C-200 (Wako Pure Chemical Industries, Ltd.) was employed. ¹H NMR and ¹³C NMR spectra were recorded using a Bruker Ultrashield Plus Avance 400 spectrometer. Relative chemical shifts were reported in δ (ppm) in DMSO-*d*₆ or in CDCl₃ with tetramethylsilane as an internal standard. Low- and high-resolution mass spectra were recorded on a JMS-T1000LC AccuTOF and Bruker Daltonics microTOF-2focus. RP-HPLC was performed with linear gradients of acetonitrile and H₂O containing 0.1% (v/v) TFA (column: Cosmosil μ C₁₈ AR-II (4.6 \times 250 mm) for analytical runs, Cosmosil μ C₁₈ AR-II (20 \times 250 mm) for preparative runs. UV absorbance spectra were recorded on a Jasco V-650 spectrophotometer using a 1.0 cm path length quartz cuvette. Fluorescent spectra were recorded on a Jasco FP-6600 spectrofluorometer using a 1.0 cm path length quartz cuvette. Measurements of fluorescent intensity on 96-well plates were performed on a Wallac ARVO MX (Perkin-Elmer).

Peptide Synthesis. The protected peptide of δ C1b(247–281) was manually constructed on a Novasyn TGR resin (0.25 mmol/g) by standard Fmoc-based solid phase peptide synthesis (SPPS). Fmoc-protected amino acid derivatives (5 equiv) were successively condensed using 1,3-diisopropylcarbodiimide (DIPCI) (5 equiv) in the presence of 1-hydroxybenzotriazole \cdot H₂O (HOBt \cdot H₂O) (5 equiv) in DMF (2 mL) (90 min treatment). The following side-chain protecting groups were used: Boc for Lys; Pbf for Arg; OBU^t for Asp; Trt for Asn, Cys, and His; Bu^t for Ser, Thr, and Tyr. The Fmoc group was deprotected with 20% (v/v) piperidine in DMF (2 mL) for 15 min. The resulting protected peptide was cleaved from the resin and deprotected with TFA-thioanisole-*m*-cresol-triisopropylsilane (TIS) (89:7.5:2.5:1, v/v) (90 min treatment). Deprotected peptides were

* To whom correspondence should be addressed. E-mail: nomura.mr@tmd.ac.jp; tamamura.mr@tmd.ac.jp. Phone: +81-3-5280-8036. Fax: +81-3-5280-8039.

[†] Tokyo Medical and Dental University.

[‡] National Institutes of Health.

washed with cold Et₂O three times. The product was then purified by RP-HPLC. The protected peptides of dansyl-labeled δ C1b(221–246) were manually elongated on an Fmoc-His(Trt)-Trt(2-Cl)-resin (0.42 mmol/g) by Fmoc-based SPPS as in the synthesis of δ C1b(247–281). The following side-chain protecting groups were used: Boc for Lys; Pbf for Arg; OBu^t for Asp, Glu; Trt for Asn, Cys, Gln, and His; Bu^t for Ser, Thr, and Tyr. At the dansyl-labeled position, Fmoc-Lys(DnsGly)-OH was used. The resulting protected peptides were cleaved from the resin with trifluoroethanol (TFE)-AcOH-DCM (1:1:3, v/v) (2 h treatment), followed by thioesterification. Deprotection was performed as in the synthesis of δ C1b(247–281). The product was then purified by RP-HPLC. Mass data and chemical yields of these peptides are described in Supporting Information.

Thioesterification. Thioesterification was performed with ethyl mercaptopropionate (20 equiv), HOBt·H₂O (10 equiv), and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDCI)·HCl (10 equiv) in DMF (1 mL) (–20 °C, overnight). DMF was removed by evaporation, and the crude products were washed with H₂O.

Native Chemical Ligation. Dansyl-labeled δ C1b(221–246) (1.8 mg, 0.5 μ mol) and the δ C1b(247–281) (1.9 mg, 0.5 μ mol) were dissolved in 500 μ L of 100 mM phosphate buffer (pH 8.5) containing 6 M guanidine hydrochloride (Gn·HCl) containing 2 mM EDTA and tris(2-carboxyethyl)phosphine hydrochloride (TCEP·HCl) (1.4 mg, 5 μ mol). Thiophenol (15 mL, 3%) was then added to the mixture. The ligation reaction was performed at 37 °C under an N₂ atmosphere. Progress of the ligation reaction was monitored by RP-HPLC (gradient: 25–45% of acetonitrile/0.1% TFA against H₂O/0.1% TFA). The product was subjected to gel filtration with Sephadex G-10 and then purified by RP-HPLC. Mass data of these peptides are described in Supporting Information.

Folding of δ C1b Domains. Purified peptides were dissolved in 50 mM Tris·HCl (pH 7.4) with 5 mM DTT, incubated for 15 min at 30 °C, and then stored at –20 °C with 20% glycerol. The peptide solution was dialyzed against 50 mM Tris·HCl (pH 7.4) containing 150 mM NaCl, 1 mM DTT, and 0.1 mM ZnCl₂ using a Slide-A-Lyzer Dialysis Cassette 2000 MWCO (Thermo Scientific).

[³H]PDBu Binding Assay. [³H]PDBu binding to the δ C1b domains was measured using the poly(ethylene glycol) precipitation assay as described previously (18, 19) with minor modifications. To determine the dissociation constants (K_d) and numbers of binding sites (B_{max}) for the dansyl-labeled δ C1b domains, saturation curves with increasing concentrations of [³H]PDBu were obtained in triplicate. 250 μ L of the assay mixture contained 50 mM Tris·HCl (pH 7.4), 1 mM ethylenedis(oxyethylenitrilo)tetraacetic acid (EGTA), 0.1 mg/mL phosphatidylserine, 5 mg/mL bovine immunoglobulin G, variable concentrations of [³H]PDBu, and, for those tubes used to determine nonspecific binding, an excess of nonradioactive PDBu. After addition of peptides stored in 0.015% Triton X-100, binding was carried out at 18 °C for 10 min. Samples were incubated on ice for 10 min. 200 μ L of 35% poly(ethylene glycol) in 50 mM Tris·HCl (pH 7.4) was added, and the samples were incubated on ice for an additional 10 min. The tubes were centrifuged at 4 °C (12 200 rpm, 15 min), and a 100 μ L aliquot of each supernatant was then transferred to a scintillation vial for determination of the amount of the free [³H]PDBu. After the remaining supernatant was aspirated off, the bottom of each centrifuge tube was cut off just above the pellet and transferred to a scintillation vial for the determination of the amount of the total bound [³H]PDBu. Dissociation constants (K_d) were calculated by Scatchard analysis.

CD Measurement. CD spectra were recorded on a Jasco J-720 spectropolarimeter at 25 °C. The measurements were

performed at 0.1 nm spectral resolution using a 0.5 cm path length quartz cuvette. Each spectrum represents the average of 40 scans, and the scan rate was 100 nm/min. Measurements were performed in a Tris·HCl (pH 7.4) buffer containing 1 mM DTT and 150 mM NaCl.

Fluorescence Measurement. Ligand titration was performed in 1 mL of dialysis buffer containing 0.5 μ M dialyzed dansyl-labeled δ C1b domain and 5 μ g/mL phosphatidylserine at 25 °C. After each addition of ligands, the mixture was incubated at the same temperature for 10 min. Fluorescent emission spectra (λ_{ex} = 330 nm; slit width: 20 nm for excitation, 40 nm for emission) were obtained throughout the addition of ligands. For experiments using 96-cell plates, Dansyl-labeled δ C1b domain solution (dialysis buffer containing 0.5 μ M dialyzed peptides and 5 μ g/mL phosphatidylserine) was prepared and incubated for 10 min at room temperature. Fluorescence of dansyl-labeled δ C1b domain was measured using an excitation filter of 355 nm (half-width: 40 nm) and an emission filter of 460 nm (half-width: 25 nm), respectively.

Molecular Modeling. Molecular modeling was performed using Sybyl 7.1 (Tripos Inc., St. Louis, MO). Predictive models of dansyl-labeled δ C1b domain analogues were built by substitution of Lys(Dns-Gly) for residues Tyr238, Ser240, or Thr242 that were contained in the crystal structure of δ C1b domain (PDB 1PTR) (20). Energy-minimization was performed on the Lys(Dns-Gly) moiety using the Tripos force field and Gasteiger-Huckel charge parameters.

RESULTS AND DISCUSSION

Design of Fluorescent-Labeled PKC δ C1b Domains.

Residues 221–281 of PKC δ forming the C1b domain represent the starting sequence we used for modification. To identify the optimal amino acid position for fluorescent labeling, Tyr238, Ser240, and Thr242 were selected for evaluation. Our choice was based on the following rationale: First, these residues are located at the edge of the binding pocket of the C1b domain as shown by the structure of δ C1b-phorbol ester complex (20). Second, site-directed mutagenesis had shown that Ser240 was not necessary for the phorbol ester binding and that the δ C1b domain mutants T242G, T242S, and T242V had only minimal effects on the binding affinity of PDBu (2.1-, 1.1-, and 3.2-fold, respectively) (21). Third, replacement of Tyr by Gly in position 238 reduced binding affinity of [³H]PDBu by 60-fold, but maintained nanomolar affinity (K_d = 48 \pm 3.0 nM), which might be sufficient for the detection of PKC ligands (21). A chemically modified lysine was utilized for fluorescent labeling. For this study, a dansyl group was adopted because of its small molecular size and larger Stokes shift compared to NBD (22). Since the flexibility of the dansyl moiety might contribute to its sensitivity to ligand binding to the δ C1b domain, glycine was incorporated between the ϵ -amino group of lysine and the dansyl moiety as a linker to construct Lys(Dns-Gly) (Supporting Information Scheme S1). Three δ C1b domain analogues, in which Lys(Dns-Gly) was substituted for Tyr238, Ser240, or Thr242, were designed and designated as Y238K(DnsG), S240K(DnsG), and T242K(DnsG), respectively. Predictive structural models of the dansyl-labeled δ C1b domains were constructed based on the crystal structure of the δ C1b domain (PDB entry 1PTR) utilizing Sybyl 7.1 (Figure 1). The models showed that the dansyl moieties of S240K(DnsG) and T242K(DnsG) are located outside the binding pocket, whereas the dansyl moiety of Y238K(DnsG) was located inside.

Synthesis of Dansyl-Labeled δ C1b Domain Analogues.

Fmoc-protected Lys(Dns-Gly) (4) was synthesized as described in Supporting Information Scheme S1. δ C1b domain analogues were synthesized based on the standard Fmoc solid-phase peptide synthesis (SPPS) (23). For an efficient synthesis of




Figure 1. Structural models of dansyl-labeled δ C1b analogues. (A) Y238K(DnsG), (B) S240K(DnsG), and (C) T242K(DnsG). Space-filling models indicate phorbol esters and zinc atoms.




Figure 2. Schematic representation of construction of dansyl-labeled δ C1b. (i) 100 mM phosphate buffer (pH 8.5), 6 M $\text{Gn}\cdot\text{HCl}$, 2 mM EDTA, TCEP $\cdot\text{HCl}$, thiophenol, N_2 , 37 °C; (ii) 50 mM Tris $\cdot\text{HCl}$ (pH 7.4), 150 mM NaCl, 1 mM DTT, 0.1 mM ZnCl_2 , 4 °C.

dansyl-labeled δ C1b domain analogues, a native chemical ligation (NCL) method was adopted (18, 24). Three N-terminal peptide fragments (dansyl-labeled δ C1b(221–246)) and a common C-terminal peptide fragment (δ C1b(247–281)) were separately synthesized. A purified δ C1b(247–281) and three dansyl-labeled δ C1b(221–246) fragments were condensed by an NCL method (Figure 2). The ligation reaction was performed with 0.8 mM of each peptide fragment in 100 mM phosphate buffer (pH 8.5) containing 6 M $\text{Gn}\cdot\text{HCl}$, 2 mM EDTA, and 3% thiophenol at 37 °C. The progress of the ligation reaction was monitored by HPLC (Supporting Information). The condensed δ C1b domains were identified by ESI-TOF-mass spectra (Supporting Information Table S1). The purified peptides were lyophilized and obtained as powders. Total yields of NCL were 38% for Y238K(DnsG), 48% for S240K(DnsG), and 41% for T242K(DnsG). Folding of the synthetic δ C1b domain was performed by dialysis against Zn^{2+} containing buffer (50 mM Tris $\cdot\text{HCl}$ (pH 7.4), 150 mM NaCl, 1 mM DTT, 0.1 mM ZnCl_2) at 4 °C.

Characterization of Synthetic δ C1b Analogues. The apparent [^3H]PDBu binding affinity of the dansyl-labeled δ C1b domains was evaluated by the method described previously (18, 19). S240K(DnsG) and T242K(DnsG) showed K_d values comparable to that of the wild type. However, B_{max} values were 6% for S240K(DnsG) and 11% for T242K(DnsG) compared to the wild type (Table 1). The results indicate that dansyl-labeling might partly impair the efficiency of correct folding of the synthetic δ C1b domain. Y238K(DnsG) did not possess significant binding affinity for PDBu, consistent with the predictions from the modeling. We conclude that the dansyl-labeled δ C1b domains maintain potent binding activity and correct folding, at least for an appreciable proportion of the

Table 1. Binding Activity of the Synthetic δ C1b Analogues to [^3H]PDBu

peptides	K_d (nM) ^a	B_{max} (pmol/mg) ^b
wild type	0.34 ± 0.08	38000
Y238K(DnsG)	n.d. ^c	11
S240K(DnsG)	0.18 ± 0.05	2100
T242K(DnsG)	0.35 ± 0.04	3700

^a Dissociation constant for the synthetic δ C1b binding to [^3H]PDBu. Mean \pm SEM. ^b Numbers of binding sites. ^c Not determined.

product, in those cases in which the dansyl group is located outside the binding pocket.

To estimate the influence of dansyl-labeling on folding of δ C1b domain, circular dichroism (CD) spectroscopy of S240K(DnsG) and T242K(DnsG) was performed for comparison before and after dialysis (Figure 3). Since the CD spectrum of the synthetic δ C1b(231–281) is similar to that of the recombinant δ C1b domain (18), Y238K(DnsG)- δ C1b(231–281) was used to evaluate the effects of dansyl-labeling on folding of Y238K(DnsG) (Supporting Information Figure S3). The addition of ZnCl_2 did not cause a significant change of CD spectra of Y238K(DnsG)- δ C1b(231–281). Thus, the introduction of a dansyl group into Tyr238 might interfere correct folding. The CD spectra of both of the dansyl-labeled δ C1b domains before dialysis showed broad minima around 205 nm, suggesting random coil structures (25). CD spectra of the dialyzed dansyl-labeled δ C1b domains exhibited decreases of negative cotton effects around 205 nm, which were similar to those of recombinant and synthetic δ C1b domains (18, 25).

The apparent [^3H]PDBu binding affinities and CD spectra of the dansyl-labeled δ C1b domains, S240K(DnsG) and




Figure 3. Changes of CD spectra of dansyl-labeled δ C1b analogues, S240K(DnsG) (A) and T242K(DnsG) (B). Blue and black plots show profiles before and after dialysis against Zn^{2+} containing buffer, respectively.




Figure 4. Fluorescent spectra obtained by ligand titration experiments for dansyl-labeled δ C1b analogues. Panels A–C show titrations of PDBu, PMA, and PDA against S240K(DnsG), respectively. Panels D–F show titrations of PDBu, PMA, and PDA against T242K(DnsG), respectively. Dansyl-labeled δ C1b analogue, 0.5 μM ; buffer, 50 mM Tris·HCl (pH 7.4), 150 mM NaCl, 1 mM DTT, 0.1 mM ZnCl_2 , 5 $\mu\text{g/mL}$ phosphatidylserine; ligand, 0.02, 0.06, 0.1, 0.14, 0.18, 0.22, 0.26, 0.3 equiv, $\lambda_{\text{ex}} = 330$ nm.

T242K(DnsG), demonstrated that insertion of dansyl groups at Ser 240 and at Thr 242 maintained correct folding and strong ligand binding affinity comparable to that of the wild type, although involving reduction of the stability of the domains.

Titration of Ligands to Fluorescent-Labeled δ C1b Domain Analogues. To evaluate the fluorescent properties of dansyl-labeled δ C1b domain, fluorescent emission spectra were measured during ligand titration. As test ligands, the phorbol esters PDBu ($K_i = 0.72 \pm 0.06$ nM), phorbol 12-myristate 13-acetate (PMA) ($K_i = 0.14 \pm 0.04$ nM), and phorbol 12,13-diacetate (PDA) ($K_i = 68.9 \pm 5.9$ nM), were employed. Values of K_i were determined by competitive binding assays using [^3H]PDBu (Supporting Information). Fluorescent titration experiments showed that the spectra of the dansyl-labeled δ C1b domain analogues changed according to the ligand concentration. S240K(DnsG) showed 1.3-, 1.8-, and 1.2-fold increases in fluorescent intensity and blue shifts in the emission maxima upon additions of PDBu, PMA, and PDA, respectively (Figures 4A–C). T242K(DnsG) showed 1.3-, 2.6-, and 1.1-fold increases in fluorescent intensity and blue shifts in the emission maxima upon additions of PDBu, PMA, and PDA, respectively (Figures 4D–F). The rank order of increases in fluorescent intensity upon addition of the above ligands to S240K(DnsG) and T242K(DnsG) thus corresponded to that of their K_i values.

Since dansyl-Gly showed stronger fluorescent intensity in a hydrophobic environment than in a hydrophilic environment

(Supporting Information Figure S1), the increases in fluorescence intensity upon ligand titration of S240K(DnsG) and T242K(DnsG) suggested that the environment surrounding the dansyl moiety was changed to become more hydrophobic upon ligand binding (26–28). As predicted in the modeling study, the dansyl group was not located in the binding pocket, preventing binding. Even after ligand binding, the dansyl group will still be located outside the binding pocket. Thus, the binding of ligands to the binding pocket must make the environment surrounding the dansyl more hydrophobic, possibly due to interactions between dansyl and the long alkyl chains of the ligands. In addition, T242K(DnsG) showed stronger fluorescence intensity than did S240K(DnsG). This phenomenon corresponds to their relative B_{max} values observed in the [^3H]PDBu binding assay (Figures 1B, C, Table 1). A reason could be the hydrogen bonding network at the binding site of phorbol ester on the δ C1b domain. The C20 hydroxy group of the phorbol ester accepts a hydrogen bond from the main-chain NH of T242 (20). Thus, the stronger fluorescent intensity of T242K(DnsG) could be due to a closer distance to the bound ligand. Furthermore, saturation of the increase in fluorescent intensity was observed when the ligand concentration reached 0.05–0.1 μM (10–20% of the peptide concentration) (Figure 5). This result is consistent with the B_{max} values of dansyl-labeled δ C1b: 6–11% of the wild type. The K_d values based on titration of ligands to the dansyl-labeled δ C1b domains were evaluated (Table 2). As a control experiment, S240K(DnsG) dialyzed without Zn^{2+} did not






Figure 5. Plots of change of fluorescence intensity from titration experiments using S240K(DnsG) (A) and T242K(DnsG) (B). Dansyl-labeled δC1b analogue, $0.5 \mu\text{M}$; square, PMA; round, PDBu; triangle, PDA.



DAG-lactone derivative

Figure 6. Plots of change of fluorescence intensity from 96-well plates-based titration experiments of S240K(DnsG) (A) and T242K(DnsG) (B). cross, PMA; circle, PDBu; square, DAG-lactone derivative.

Table 2. K_d Values of the Fluorescent-Labeled δC1b Domain Analogues Based on Titration of Ligands

compound	S240K(DnsG) K_d (nM) ^a	T242K(DnsG) K_d (nM) ^a
PMA	20.6	121.6
PDBu	5.83	110
PDA	Not convergent	Not fitting

^aDissociation constant for the fluorescent-labeled δC1b domain analogues to each compound was calculated.

show any significant increase in fluorescent intensity upon the addition of PDBu (Supporting Information Figure S2), suggesting that correct folding involving zinc-finger formation is critical for ligand binding. The detection limit might be the level of the fluorescent intensity of PDA. The results of titration experiments indicate that, upon ligand binding to correctly folded C1b domains, the site surrounding the ligand binding pocket becomes more hydrophobic. Even if some uncertainty remains about the relative contributions of the mechanisms leading to this change in hydrophobicity, the core finding is that ligand binding was detected by an increase in fluorescent intensity, which corresponds to binding affinity. The binding activity of ligands can be possibly evaluated by increases in fluorescent intensity upon the consideration of LogP values.

S240K(DnsG) and T242K(DnsG) were employed in fluorescent experiments utilizing 96-well plates for initial assessment of their suitability to high-throughput screening. Plots of changes of fluorescent intensity against the ligand concentration showed dose-dependent curves similar to those in titration experiments (Figure 6). The results indicate that the present fluorescent-

responsive C1b domains can be used for screening of novel PKC pharmacophores.

CONCLUSIONS

In this study, three kinds of dansyl-labeled δC1b domains, Y238K(DnsG), S240K(DnsG), and T242K(DnsG), were synthetically constructed in an efficient way by utilizing Fmoc-SPPS and an NCL method. The results of CD measurements and [³H]PDBu binding assays indicated that the position of dansyl-labeling was critical for maintenance of native functions including proper folding. The ligand titration of dansyl-labeled δC1b showed that the change of fluorescent spectra corresponded to the K_i values of the ligands. Furthermore, S240K(DnsG) and T242K(DnsG) were utilized for measurements using a 96-well plate-based format, indicating that evaluation of ligand binding could be performed in a high-throughput fashion. The present fluorescent-responsive domains were successfully utilized in vitro. However, through optimization of the stability of the fluorescent-labeled δC1b domain, these domains might also be adapted for cell-based assays as efficient DAG sensors.

ACKNOWLEDGMENT

The authors thank Professor Kazunari Akiyoshi (Graduate School of Engineering, Kyoto University) for assistance in the CD experiments. This study was supported in part by the Naito Foundation for Science (to W. N.) and in part by the Intramural Research Program of the NIH, Center for Cancer Research, National Cancer Institute. N. O. is supported by the Japan Society for Promotion of Science.

Supporting Information Available: Detailed materials and methods. This material is available free of charge via the Internet at <http://pubs.acs.org>.

LITERATURE CITED

- (1) Nishizuka, Y. (1992) Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. *Science* 258, 607–614.
- (2) Newton, A. C. (1995) Protein kinase C: structure, function, and regulation. *J. Biol. Chem.* 270, 28495–28498.
- (3) Watanabe, T., Ono, Y., Taniyama, Y., Hazama, K., Igarashi, K., Ogita, K., Kikkawa, U., and Nishizuka, Y. (1992) Cell division arrest induced by phorbol ester in CHO cells overexpressing protein kinase C-delta subspecies. *Proc. Natl. Acad. Sci. U.S.A.* 89, 10159–10163.
- (4) Mischak, H., Pierce, J. H., Goodnight, J., Kazanietz, M. G., Blumberg, P. M., and Mushinski, J. F. (1993) Phorbol ester-induced myeloid differentiation is mediated by protein kinase C-alpha and -delta and not by protein kinase C-beta II, -epsilon, -zeta, and -eta. *J. Biol. Chem.* 268, 20110–20115.
- (5) Li, C., Wernig, E., Leitges, M., Hu, Y., and Xu, Q. (2003) Mechanical stress-activated PKCdelta regulates smooth muscle cell migration. *FASEB J.* 17, 2106–2108.
- (6) Ghayur, T., Hugunin, M., Talanian, R. V., Ratnofsky, S., Quinlan, C., Emoto, Y., Pandey, P., Datta, R., Huang, Y., Kharbanda, S., Allen, H., Kamen, R., Wong, W., and Kufe, D. (1996) Proteolytic activation of protein kinase C delta by an ICE/CED 3-like protease induces characteristics of apoptosis. *J. Exp. Med.* 184, 2399–2404.
- (7) Humphries, M. J., Limesand, K. H., Schneider, J. C., Nakayama, K. I., Anderson, S. M., and Reyland, M. E. (2006) Suppression of apoptosis in the protein kinase Cdelta null mouse in vivo. *J. Biol. Chem.* 281, 9728–9737.
- (8) Alkon, D. L., Sun, M. K., and Nelson, T. J. (2007) PKC signaling deficits: a mechanistic hypothesis for the origins of Alzheimer's disease. *Trends Pharmacol. Sci.* 28, 51–60.
- (9) Churchill, E., Budas, G., Vallentin, A., Koyanagi, T., and Mochly-Rosen, D. (2008) PKC isozymes in chronic cardiac disease: possible therapeutic targets? *Annu. Rev. Pharmacol. Toxicol.* 48, 569–599.
- (10) O'Brian, C. A., Ward, N. E., Stewart, J. R., Chu, F., Mackay, H. J., and Twelves, C. (2001) Prospects for targeting protein kinase C isozymes in the therapy of drug-resistant cancer—an evolving story. *Cancer Metastasis Rev.* 20, 95–100.
- (11) Tamamura, H., Sigano, D. M., Lewin, N. E., Blumberg, P. M., and Marquez, V. E. (2004) Conformationally constrained analogues of diacylglycerol. 20. The search for an elusive binding site on protein kinase C through relocation of the carbonyl pharmacophore along the sn-1 side chain of 1,2-diacylglycerol lactones. *J. Med. Chem.* 47, 644–655.
- (12) Tamamura, H., Sigano, D. M., Lewin, N. E., Peach, M. L., Nicklaus, M. C., Blumberg, P. M., and Marquez, V. E. (2004) Conformationally constrained analogues of diacylglycerol (DAG). 23. Hydrophobic ligand-protein interactions versus ligand-lipid interactions of DAG-lactones with protein kinase C (PK-C). *J. Med. Chem.* 47, 4858–4864.
- (13) Marquez, V. E., and Blumberg, P. M. (2003) Synthetic diacylglycerols (DAG) and DAG-lactones as activators of protein kinase C (PK-C). *Acc. Chem. Res.* 36, 434–443.
- (14) Morii, T., Sugimoto, K., Makino, K., Otsuka, M., Imoto, K., and Mori, Y. (2002) A new fluorescent biosensor for inositol triphosphate. *J. Am. Chem. Soc.* 124, 1138–1139.
- (15) Venkatraman, P., Nguyen, T. T., Sainlos, M., Bilsel, O., Chitta, S., Imperiali, B., and Stern, L. J. (2007) Fluorogenic probes for monitoring peptide binding to class II MHC proteins in living cells. *Nat. Chem. Biol.* 3, 201–202.
- (16) Joshi, B. P., and Lee, K. H. (2008) Synthesis of highly selective fluorescent peptide probes for metal ions: tuning selective metal monitoring with secondary structure. *Bioorg. Med. Chem.* 16, 8501–8509.
- (17) Simard, J. R., Grütter, C., Pawar, V., Aust, B., Wolf, A., Rabiller, M., Wulfert, S., Robubi, A., Klüter, S., Ottmann, C., and Rauh, D. (2009) High-throughput screening to identify inhibitors which stabilize inactive kinase conformations in p38 α . *J. Am. Chem. Soc.* 131, 18478–18488.
- (18) Ohashi, N., Nomura, W., Kato, M., Narumi, T., Lewin, N. E., Blumberg, P. M., and Tamamura, H. (2009) Synthesis of protein kinase C δ C1b domain by native chemical ligation methodology and characterization of its folding and ligand binding. *J. Pept. Sci.* 10, 642–646.
- (19) Kazanietz, M. G., Areces, L. B., Bahador, A., Mischak, H., Goodnight, J., Mushinski, J. F., and Blumberg, P. M. (1993) Characterization of ligand and substrate specificity for the calcium-dependent and calcium-independent protein kinase C isozymes. *Mol. Pharmacol.* 44, 298–307.
- (20) Zhang, G., Kazanietz, M. G., Blumberg, P. M., and Hurley, J. H. (1995) Crystal structure of the cys2 activator-binding domain of protein kinase C delta in complex with phorbol ester. *Cell* 81, 917–924.
- (21) Kazanietz, M. G., Wang, S., Milne, G. W., Lewin, N. E., Liu, H. L., and Blumberg, P. M. (1995) Residues in the second cysteine-rich region of protein kinase C delta relevant to phorbol ester binding as revealed by site-directed mutagenesis. *J. Biol. Chem.* 270, 21852–21859.
- (22) Soini, E., and Hemmila, I. (1979) Fluoroimmunoassay: present status and key problems. *Clin. Chem.* 25, 353–361.
- (23) Irie, K., Oie, K., Nakahara, A., Yanai, Y., Ohigashi, H., Wender, P. A., Fukuda, H., Konishi, H., and Kikkawa, U. (1998) Molecular basis for protein kinase C isozyme-selective binding: the synthesis, folding, and phorbol ester binding of the cysteine-rich domains of all protein kinase C isozymes. *J. Am. Chem. Soc.* 120, 9159–9167.
- (24) Dawson, P. E., Churchill, M. J., Ghadiri, M. R., and Kent, S. B. H. (1997) Chemical protein synthesis by solid phase ligation of unprotected peptide segments. *J. Am. Chem. Soc.* 119, 4325–4329.
- (25) Zimenkov, Y., Dublin, S. N., Ni, R., Tu, R. S., Breedveld, V., Apkarian, R. P., and Conticelli, V. P. (2006) Rational design of a reversible pH-responsive switch for peptide self-assembly. *J. Am. Chem. Soc.* 128, 6770–6771.
- (26) Ikeda, H., Nakamura, M., Ise, N., Oguma, N., Nakamura, A., Ikeda, T., Toda, F., and Ueno, A. (1996) Fluorescent cyclodextrins for molecule sensing: fluorescent properties, NMR characterization, and inclusion phenomena of n-dansylleucine-modified cyclodextrins. *J. Am. Chem. Soc.* 118, 10980–10988.
- (27) Ikunaga, T., Ikeda, H., and Ueno, A. (1999) The effects of avidin on inclusion phenomena and fluorescent properties of biotin-appended dansyl-modified β -cyclodextrin. *Chem.—Eur. J.* 5, 2698–2704.
- (28) Matsumura, S., Sakamoto, S., Ueno, A., and Mihara, H. (2000) Construction of α -helix peptides with β -cyclodextrin and dansyl units and their conformational and molecular sensing properties. *Chem.—Eur. J.* 6, 1781–1788.

BC100414A

Supporting Information

Fluorescent-responsive Synthetic C1b Domains of Protein Kinase C δ as Reporters of Specific High Affinity Ligand Binding

Nami Ohashi,[†] Wataru Nomura,^{*,†} Tetsuo Narumi,[†] Nancy E. Lewin,[‡] Kyoko Itotani,[†] Peter M. Blumberg,[‡] and Hirokazu Tamamura^{*,†}

[†]*Department of Medicinal Chemistry, Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, 2-3-10 Kandasurugadai, Chiyoda-ku, Tokyo 101-0062, Japan,*

[‡]*Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA*

*correspondence to nomura.mr@tmd.ac.jp or [tamamura.mr@tmd.ac.jp](mailto:tamura.mr@tmd.ac.jp)

Supporting Information Figures




Figure S1. Solvent polarity dependence of fluorescent spectra of **2** (2 μM) in dioxane/PBS solvent mixtures. Dioxane content (% v/v) in dioxane/PBS mixture: 0, 20, 40, 60, 80 and 100%. λ_{ex} = 327 nm (0%), 329 nm (20%), 331 nm (40%), 333 nm (60%), 335 nm (80,100%).




Figure S2. Ligand titration for S240K(DnsG) dialyzed with 50 mM Tris·HCl (pH 7.4, 1 mM DTT, 2 mM EDTA) (without Zn^{2+}). Titration was performed in 50 mM Tris·HCl (pH